Jun. 26 at 12:59 AM
$BIAF Bioaffinity Scientists are developing a topical treatment for cutaneous malignancies and neoplasms of the skin and potentially other cancers based on our discoveries on how TCPP, the porphyrin used in CyPath® Lung, enters cancer cells. Our studies demonstrated that suppressing two cell membrane receptors kills cancer cells without harming healthy cells. This broad-spectrum vulnerability of cancer was found in lung, breast, prostate, brain, and skin cancers.
Our pipeline of therapeutics includes patented siRNA-based compounds that selectively inhibit cancer cell proliferation leading to cell death.
